InvestorsHub Logo
Followers 51
Posts 4564
Boards Moderated 0
Alias Born 12/14/2009

Re: alexander77 post# 251372

Wednesday, 11/13/2019 2:20:48 PM

Wednesday, November 13, 2019 2:20:48 PM

Post# of 690921
“11:40 am DCVax Technology: Leveraging Activated Dentritic Cells in Clinical 40 for GBM

Marnix Bosch
CTO, Northwest Biotherapeutics
Synopsis

Exploring the history, biology and development of the platform technology DCVax
Outlining the key aspects of the DCVax technology that contribute to the positive clinical results
Designed to mobilize the ENTIRE immune system
Designed to target not just one but the full set of biomarkers on the patient’s tumor
DCVax is personalized, and targets the particular biomarkers expressed on that patient’s tumor
Pinpointing highs and lows of clinical development to date”

https://glioblastoma-drugdevelopment.com/about/agenda/day-two/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News